Skip to content
10-Q

Quarterly Report

Audentes Therapeutics, Inc.

0001564590-18-027601

← back to feed
Filed
Nov 7, 2018 12:00 AM ET
Period of report

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding Q3 2018 · Oct 31, 2018 42.69M sh
Short Term Investments Q3 2018 · Sep 30, 2018 $176.35M
Short Term Investments Q3 2018 · Dec 31, 2017 $94.64M
Cash And Equivalents Q3 2018 · Sep 30, 2018 $104.34M
Cash And Equivalents Q3 2018 · Dec 31, 2017 $38.97M
Current Liabilities Q3 2018 · Sep 30, 2018 $19.25M
Current Liabilities Q3 2018 · Dec 31, 2017 $17.71M
Total Liabilities Q3 2018 · Sep 30, 2018 $27.22M
Total Liabilities Q3 2018 · Dec 31, 2017 $22.06M
Current Assets Q3 2018 · Sep 30, 2018 $285.33M
Current Assets Q3 2018 · Dec 31, 2017 $137.01M
Total Assets Q3 2018 · Sep 30, 2018 $337.77M
Total Assets Q3 2018 · Dec 31, 2017 $178.66M
Capex Q3 2018 · Sep 30, 2017 $5.03M
Operating Cash Flow Q3 2018 · Sep 30, 2017 −$61.27M
Sga Expense Q3 2018 · Sep 30, 2017 $4.34M
Sga Expense Q3 2018 · Sep 30, 2017 $12.07M
Rd Expense Q3 2018 · Sep 30, 2017 $20.87M
Rd Expense Q3 2018 · Sep 30, 2017 $54.23M
Net Income Q3 2018 · Sep 30, 2017 −$25.01M
Net Income Q3 2018 · Sep 30, 2017 −$65.86M
Operating Income Q3 2018 · Sep 30, 2017 −$25.21M
Operating Income Q3 2018 · Sep 30, 2017 −$66.3M